Jasper Therapeutics(US:JSPR) Globenewswire·2025-10-30 15:20Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper controls in manufacturing processes [3][5]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Jasper [3]. - Investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues has led to overstated business and financial prospects for Jasper, making public statements materially false and misleading [5]. Group 3: Impact of Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [6]. - The company announced a halt in the ETESIAN Study and paused development in asthma and SCID, alongside plans for cost-cutting measures and potential restructuring to extend its financial runway [6].